Theravance Biopharma Inc reports results for the quarter ended in June - Earnings Summary

• Theravance Biopharma Inc TBPH reported a quarterly adjusted loss of 28 cents​​ per share for the quarter ended in June, identical to the same quarter last year. The mean expectation of four analysts for the quarter was for a loss of 21 cents per share. Wall Street expected results to range from -24 cents to -19 cents per share.

• Revenue rose 3.7% to $14.26 million from a year ago; analysts expected $15.45 million.

• Theravance Biopharma Inc's reported EPS for the quarter was a loss of 34 cents​.

• The company reported a quarterly loss of $16.53 million.

• Theravance Biopharma Inc shares had risen by 13.7% this quarter and lost 14.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 3.4% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Theravance Biopharma Inc is $15.00

This summary was machine generated from LSEG data August 5 at 09:02 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)